Clinical Trial Update: Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) [Phase 4]

View source ↗

Summary

Phase 4 trial updating efficacy and safety of ranibizumab 0.5 mg given in two alternative dosing regimens in Chinese patients with neovascular age-related macul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• ranibizumab 0.5 mg (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2018-02-12